4.3 Article

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

期刊

MULTIPLE SCLEROSIS JOURNAL
卷 28, 期 13, 页码 2070-2080

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585221108080

关键词

Multiple sclerosis; biomarkers; neurofilament light; natalizumab; extended dosing interval; MRI; EDSS

资金

  1. Berit Linnea and Ragnar Bakken Foundation
  2. Swedish Research Council [201802532]
  3. Alzheimer Drug Discovery Foundation (ADDF), USA [RDAPB-201809-2016615]
  4. Swedish Alzheimer Foundation [AF-930351, AF939721, AF-968270]
  5. Hjarnfonden, Sweden [FO2019-0228]
  6. County Councils
  7. European Union Joint Program for Neurodegenerative Disorders [JPND2019-466-236]
  8. National Institute of Health (NIH), USA [1R01AG068398-01]
  9. Alzheimer's Association 2021 Zenith Award [ZEN21-848495]
  10. European Research Council [681712]
  11. Swedish State Support for Clinical Research [ALFGBG-71320, 201809-2016862]
  12. AD Strategic Fund
  13. Alzheimer's Association [ADSF-21-831377C]
  14. Olav Thon Foundation
  15. Erling-Persson Family Foundation
  16. Stiftelsen for Gamla Tjanarinnor
  17. European Union [860197, JPND2021-00694]
  18. UK Dementia Research Institute at UCL [UKDRI-1003]
  19. County Councils
  20. the ALF-agreement [ALFGBG-715986, ALFGBG-965240]

向作者/读者索取更多资源

This study investigated the effect of extending the dosing interval of natalizumab (NZ) from 4 to 6 weeks on serum neurofilament light chain (sNfL) concentrations in patients with relapsing-remitting multiple sclerosis (RRMS). The results showed that extending the NZ dosing interval did not increase axonal damage in patients with RRMS, as determined with sNfL.
Background: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with extended-interval dosing (EID) in patients with relapsing-remitting multiple sclerosis (RRMS). Objectives: We switched NZ dosing from 4-week to 6-week intervals in patients with RRMS, and investigated the effect on serum neurofilament light chain (sNfL) concentrations. Methods: We included two cohorts of patients with RRMS treated with NZ: one received the standard-interval dosing (4 weeks) at baseline, and were switched to 6-week intervals (EID4-6, N = 45). The other cohort received EID (5- or 6-week intervals) both at baseline and during follow-up (EID5/6, N = 25). Serum samples were collected in the EID4-6 cohort at every NZ infusion, for 12 months. The primary outcome was the change in sNfL concentrations after switching to EID. Results: The baseline mean sNfL concentration in the EID4-6 cohort was 10.5 ng/L (standard deviation (SD) = 6.1), and it remained unchanged at 12 months. Moreover, individual sNfL concentrations did not change significantly after extending the NZ dosing intervals. In addition, the EID4-6 and EID5/6 cohorts had similar baseline sNfL concentrations. Conclusion: We concluded that extending the NZ dosing interval did not increase axonal damage, as determined with sNfL, in patients with RRMS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据